Exagen (XGN) EV/EBITDA Multiple

Exagen Inc (XGN) - corporate logo

The EV/EBITDA price chart for Exagen Inc. (XGN), which specializes in laboratory diagnostics, confirms steady demand for rheumatology tests that provides the company with regular cash flow. The metric stands at 0.00. Revenue stability is constrained only by insurance limits and the frequency of physician referrals. Meanwhile, the business relies on a strong staff of biochemists and geneticists, complemented by experienced sales managers.

XGN Exagen: Total Company Value to Operating Income Before Depreciation Ratio in the range 11/23/2025 - 11/13/2026

exagen.com - analytical breakdowns and key metrics (XGN)

- market price and analyst price targets:
Price Chart Exagen|XGN - Analyst Median Target
- market capitalization details:
Market Capitalization XGN|XGN - Company Buyout Price
- issuer book value statistics:
Net Assets per Single Share Exagen Inc.|XGN - Book Valuation of Business|Market Capitalization to Book Value Ratio exagen.com|XGN - Company Assets
- company liabilities and liquidity data:
Total Debt to Equity Ratio Exagen Inc.|XGN - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Exagen|XGN - Company Aggregate Debts|Debts to Book Capitalization XGN|XGN - Long-Term Indebtedness|Company Short-Term Debts Exagen Inc.|Quick Liquidity exagen.com
- business earnings and investment ratios data:
XGN - Company Profit|Future Profit Exagen Inc.|XGN - Company Value to Net Income|Forward P/E Multiple Exagen|XGN - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization XGN|XGN - Operating profit before amortization|Net earnings per share (EPS TTM) Exagen Inc.|XGN - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months exagen.com|XGN - Expected net earnings per share growth this year|Expected earnings per share growth for next year Exagen Inc.
Fundamental company analysis:Exagen Diagnostics XGN
Manufactured products of exagen.com

EV/EBITDA determines the business value relative to its operating profit before interest, taxes, depreciation, and amortization. By analyzing the EV/EBITDA multiple of a capital-intensive enterprise, an investor compares market capitalization with debt and actual cash flow. The current value of 0.00 reflects the fundamental valuation of Exagen Inc. (XGN) taking into account infrastructure costs. The reliability of this metric is supported by the presence of backup systems and platform redundancy at the company's California laboratory.

Main competitors

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Agilent Tech A|Total Company Value to Operating Income Before Depreciation Ratio Quest Corp (DGX)|Illumina, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio exactsciences.com EXAS|Revvity (RVTY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|BIO - Total Company Value to Operating Income Before Depreciation Ratio|NNNN (Anbio Tech) - EV/EBITDA Multiple|Company Value to EBITDA Nordion SHC|Enterprise Value to EBITDA Ratio QDEL (QuidelOrtho)|opko.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple CDNA (CareDx Inc)|EV/EBITDA Multiple Maravai LifeSciences Holdings MRVI|Fulgent Corp - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Standard BioTools Corp (LAB)|CTKB: EV/EBITDA Multiple|Company Value to EBITDA orasure.com (OSUR)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MDxHealth|Enterprise Value to Operating Income Before Depreciation LUCD (Lucid Diagnostics, Inc.)|Enterprise Value to EBITDA Ratio PRE (Prenetics Global)|IMDX (imdxinc.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TRIB (Trinity Biotech)|Total Company Value to Operating Income Before Depreciation Ratio prophaselabs.com (PRPH)|AIMD - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CODX (Co-Diagnostics Inc) - Enterprise Value to Operating Income Before Depreciation|HSCS: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Biomerica Inc|Enterprise Value to EBITDA Ratio CDIO|onconetix.gcs-web.com (ONCO) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio VRAX (Virax Biolabs)|Bluejay Diagnostics Inc - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AWH (Vermillion)|Enterprise Value to EBITDA Multiple Accelerate Diagnostics Inc|CNTG - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ENZ (Enzo Biochem, Inc.) - Enterprise Value to Operating Income Before Depreciation|fresh2.co (FRES) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Genetic Technologies Limited|ME (23andMe Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Psychemedics Inc PMD